Search Results - "PAVLETIC, Steven"

Allogeneic hematopoietic cell transplantation in elderly patients with myelodysplastic syndromes: Considerations and challenges by Schulz, Eduard, Pavletic, Steven Z., Mina, Alain

“…Myelodysplastic syndromes/neoplasms (MDS) and related diseases are highly heterogeneous myeloid stem cell cancers that predominantly affect the elderly. The…”
Get full text

Immunotherapy in hematologic malignancies: past, present, and future by Im, Annie, Pavletic, Steven Z

“…The field of immunotherapy in cancer treatments has been accelerating over recent years and has entered the forefront as a leading area of ongoing research and…”
Get full text

Forty years of hematopoietic stem cell transplantation in Croatia: First-World options and First-World science by Pavletic, Steven Z

Get full text

EBMT−NIH−CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment by Schoemans, Helene M., Lee, Stephanie J., Ferrara, James L., Wolff, Daniel, Levine, John E., Schultz, Kirk R., Shaw, Bronwen E., Flowers, Mary E., Ruutu, Tapani, Greinix, Hildegard, Holler, Ernst, Basak, Grzegorz, Duarte, Rafael F., Pavletic, Steven Z.

“…Several international recommendations address the assessment of graft-versus-host disease (GvHD) after hematopoietic cell transplantation (HCT). This position…”
Get full text

W“H-Y” antigen/HLA complexes in chronic GVHD by Holtzman, Noa G., Pavletic, Steven Z.

Get full text

Autoimmunity Following Allogeneic Hematopoietic Stem Cell Transplantation by Buxbaum, Nataliya Prokopenko, Pavletic, Steven Z

“…Autoimmune manifestations after allogeneic hematopoietic stem cell transplantation (AHSCT) are rare and poorly understood due to the complex interplay between…”
Get full text

Intestinal microbiome and myelodysplastic syndromes: Current state of knowledge and perspectives for future by Simunic, Marin, McGraw, Kathy, Pavletic, Steven Z., Rashidi, Armin

“…The intestinal microbiome has been mechanistically linked with health and many disease processes. Cancer is no exception. Both in solid tumors and hematologic…”
Get full text

Durable discontinuation of systemic therapy for chronic graft- versus -host disease: myth or reality? by Pavletic, Steven Z, Schultz, Kirk R

Get full text

The clinical landscape of chronic graft‐versus‐host disease management in 2021 by Holtzman, Noa G., Pavletic, Steven Z.

“…Summary Chronic graft‐versus‐host disease (cGVHD) is an important systemic complication of allogeneic haematopoietic stem cell transplantation with…”
Get full text

Study protocol: Close Assessment and Testing for Chronic Graft-vs.-Host disease (CATCH) by Pidala, Joseph, Carpenter, Paul A, Onstad, Lynn, Pavletic, Steven Z, Hamilton, Betty K, Chen, George L, Farhadfar, Nosha, Hall, Marcie, Lee, Stephanie J

“…Chronic graft-versus-host disease (GVHD) is an immune-mediated disorder that causes significant late morbidity and mortality following allogeneic hematopoietic…”
Get full text

Oral Complications of Chronic Graft-Versus-Host Disease by Fall-Dickson, Jane M, Pavletic, Steven Z, Mays, Jacqueline W, Schubert, Mark M

“…The increasing clinical indications for hematopoietic stem cell transplantation (HSCT) and improved clinical care throughout and following HSCT have led to not…”
Get full text

Risk factors for acute GVHD and survival after hematopoietic cell transplantation by Jagasia, Madan, Arora, Mukta, Flowers, Mary E.D., Chao, Nelson J., McCarthy, Philip L., Cutler, Corey S., Urbano-Ispizua, Alvaro, Pavletic, Steven Z., Haagenson, Michael D., Zhang, Mei-Jie, Antin, Joseph H., Bolwell, Brian J., Bredeson, Christopher, Cahn, Jean-Yves, Cairo, Mitchell, Gale, Robert Peter, Gupta, Vikas, Lee, Stephanie J., Litzow, Mark, Weisdorf, Daniel J., Horowitz, Mary M., Hahn, Theresa

“…Risk factors for acute GVHD (AGVHD), overall survival, and transplant-related mortality were evaluated in adults receiving allogeneic hematopoietic cell…”
Get full text

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study by Cutler, Corey, Lee, Stephanie J., Arai, Sally, Rotta, Marcello, Zoghi, Behyar, Lazaryan, Aleksandr, Ramakrishnan, Aravind, DeFilipp, Zachariah, Salhotra, Amandeep, Chai-Ho, Wanxing, Mehta, Rohtesh, Wang, Trent, Arora, Mukta, Pusic, Iskra, Saad, Ayman, Shah, Nirav N., Abhyankar, Sunil, Bachier, Carlos, Galvin, John, Im, Annie, Langston, Amelia, Liesveld, Jane, Juckett, Mark, Logan, Aaron, Schachter, Levanto, Alavi, Asif, Howard, Dianna, Waksal, Harlan W., Ryan, John, Eiznhamer, David, Aggarwal, Sanjay K., Ieyoub, Jonathan, Schueller, Olivier, Green, Laurie, Yang, Zhongming, Krenz, Heidi, Jagasia, Madan, Blazar, Bruce R., Pavletic, Steven

“…Belumosudil, an investigational oral selective inhibitor of Rho-associated coiled-coil–containing protein kinase 2 (ROCK2), reduces type 17 and follicular T…”
Get full text

Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease by Brudno, Jennifer N, Somerville, Robert P T, Shi, Victoria, Rose, Jeremy J, Halverson, David C, Fowler, Daniel H, Gea-Banacloche, Juan C, Pavletic, Steven Z, Hickstein, Dennis D, Lu, Tangying L, Feldman, Steven A, Iwamoto, Alexander T, Kurlander, Roger, Maric, Irina, Goy, Andre, Hansen, Brenna G, Wilder, Jennifer S, Blacklock-Schuver, Bazetta, Hakim, Frances T, Rosenberg, Steven A, Gress, Ronald E, Kochenderfer, James N

“…Progressive malignancy is the leading cause of death after allogeneic hematopoietic stem-cell transplantation (alloHSCT). After alloHSCT, B-cell malignancies…”
Get full text

A contemporary downtrend in chronic GVHD? by El Jurdi, Najla, Pavletic, Steven Z.

Get full text

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation by Kochenderfer, James N., Dudley, Mark E., Carpenter, Robert O., Kassim, Sadik H., Rose, Jeremy J., Telford, William G., Hakim, Frances T., Halverson, David C., Fowler, Daniel H., Hardy, Nancy M., Mato, Anthony R., Hickstein, Dennis D., Gea-Banacloche, Juan C., Pavletic, Steven Z., Sportes, Claude, Maric, Irina, Feldman, Steven A., Hansen, Brenna G., Wilder, Jennifer S., Blacklock-Schuver, Bazetta, Jena, Bipulendu, Bishop, Michael R., Gress, Ronald E., Rosenberg, Steven A.

“…New treatments are needed for B-cell malignancies persisting after allogeneic hematopoietic stem cell transplantation (alloHSCT). We conducted a clinical trial…”
Get full text

Oral and Gut Microbiome Alterations in Oral Chronic GVHD Disease: Results from Close Assessment and Testing for Chronic GVHD (CATCH Study) by Rashidi, Armin, Pidala, Joseph, Hamilton, Betty K., Pavletic, Steven Z., Kim, Katie, Zevin, Alex, Mays, Jacqueline W., Lee, Stephanie J.

“…Whether and how the oral microbiome and its changes in allogeneic hematopoietic cell transplantation (alloHCT) recipients may contribute to oral chronic GVHD…”
Get full text

Red cell distribution width as a new prognostic biomarker in refractory chronic graft- versus -host disease by Schulz, Eduard, Pirsl, Filip, Holtzman, Noa G, Beshensky, David, Cowen, Edward W, Mitchell, Sandra A, Steinberg, Seth M, Pavletic, Steven Z

Get full text

Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria by Arai, Sally, Jagasia, Madan, Storer, Barry, Chai, Xiaoyu, Pidala, Joseph, Cutler, Corey, Arora, Mukta, Weisdorf, Daniel J., Flowers, Mary E.D., Martin, Paul J., Palmer, Jeanne, Jacobsohn, David, Pavletic, Steven Z., Vogelsang, Georgia B., Lee, Stephanie J.

“…In 2005, the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic GVHD proposed a new scoring system for…”
Get full text

Diagnosis and treatment of bronchiolitis obliterans syndrome accessible universally by Hakim, Anas, Cooke, Kenneth R., Pavletic, Steven Z., Khalid, Mohammad, Williams, Kirsten M., Hashmi, Shahrukh K.

“…The incidence of bronchiolitis obliterans syndrome (BOS), a devastating manifestation of chronic graft-versus-host-disease, may rise globally due to steady…”
Get full text